{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:52Z","timestamp":1794047452344,"version":"4.8.0"},"reference-count":27,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with relapsed or refractory (R\/R) FL, many patients still die from progressive disease or treatment-related toxicities. In the phase Ib\/II GO29365 study (clinicaltrials.gov 02257567), the safety and efficacy of polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) versus bendamustine and rituximab (BR) alone, and polatuzumab vedotin plus bendamustine and obinutuzumab (Pola-BG) as a single-arm cohort were evaluated in patients with R\/R FL. Following the phase Ib safety run-in, patients were randomized 1:1 to receive Pola-BR or BR alone in the phase II stage; a separate non-randomized Pola-BG cohort was examined in the phase Ib\/II expansion stage. Primary endpoints included safety and tolerability (phase Ib) and positron emission tomography complete response (PET-CR) rate by independent review committee (phase II). Overall, 112 patients were enrolled (phase Ib safety run-in: Pola-BR, N=6; phase II randomized cohort: Pola-BR, N=39; BR, N=41; phase Ib\/II expansion cohort: Pola-BG, N=26). PET-CR rates were 66.7% (phase Ib safety run-in, Pola-BR); 69.2% (phase II randomized, Pola-BR); 63.4% (phase II randomized, BR); and 65.4% (phase Ib\/II expansion Pola-BG). There was a higher occurrence of cytopenias with Pola-BR and Pola-BG than with BR; serious adverse events were more frequent with Pola-BR (61.4%) and Pola-BG (46.2%) than with BR (29.3%). Overall, this analysis does not demonstrate a benefit of adding Pola to BR or BG regimens for patients with R\/R FL.<\/jats:p>","DOI":"10.3324\/haematol.2023.283557","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:28:07Z","timestamp":1695914887000},"page":"1194-1205","source":"Crossref","is-referenced-by-count":6,"title":["Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed\/refractory follicular lymphoma: a phase Ib\/II study"],"prefix":"10.3324","volume":"109","author":[{"given":"Christopher R.","family":"Flowers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u0148n\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Musick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"59742","doi-asserted-by":"crossref","unstructured":"Monga N, Nastoupil L, Garside J. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019; 98(1):175-183.","DOI":"10.1007\/s00277-018-3501-8"},{"key":"59743","doi-asserted-by":"crossref","unstructured":"Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019; 133(14):1540-1547.","DOI":"10.1182\/blood-2018-08-822148"},{"key":"59744","doi-asserted-by":"crossref","unstructured":"Salles G. How do I sequence therapy for follicular lymphoma?. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):287-294.","DOI":"10.1182\/hematology.2020000156"},{"key":"59745","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Maurer MJ, Link BK. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019; 37(2):144.","DOI":"10.1200\/JCO.18.00400"},{"key":"59746","doi-asserted-by":"crossref","unstructured":"Dornan D, Bennett F, Chen Y. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009; 114(13):2721-2729.","DOI":"10.1182\/blood-2009-02-205500"},{"key":"59747","doi-asserted-by":"crossref","unstructured":"Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs. 2011; 20(1):75-85.","DOI":"10.1517\/13543784.2011.539557"},{"key":"59748","doi-asserted-by":"crossref","unstructured":"Doronina SO, Toki BE, Torgov MY. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003; 21(7):778-784.","DOI":"10.1038\/nbt832"},{"key":"59749","doi-asserted-by":"crossref","unstructured":"Assi R, Masri N, Abou Dalle I. Polatuzumab vedotin: current role future applications in the treatment of patients with diffuse large B-cell lymphoma. Clin Hematol Int. 2021; 3(1):21.","DOI":"10.2991\/chi.k.210305.001"},{"key":"59750","doi-asserted-by":"crossref","unstructured":"Sehn LH, Herrera AF, Flowers CR. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38(2):155.","DOI":"10.1200\/JCO.19.00172"},{"key":"59751","unstructured":"European Medicines Agency. POLIVY\u00ae Summary of Product Characteristics. 2022."},{"key":"59752","unstructured":"U.S. Food and Drug Administration. POLIVY\u00ae Prescribing information. 2022."},{"key":"59753","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Barbui AM, Canales MA. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018; 36(23):2395-2404.","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"59754","doi-asserted-by":"crossref","unstructured":"Townsend W, Hiddemann W, Buske C. Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the GALLIUM study. Hemasphere. 2022; 6(S3):107-108.","DOI":"10.1097\/01.HS9.0000843716.68800.8b"},{"key":"59755","doi-asserted-by":"crossref","unstructured":"Sehn LH, Herrera AF, Flowers CR. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38(2):155-165.","DOI":"10.1200\/JCO.19.00172"},{"key":"59756","doi-asserted-by":"crossref","unstructured":"Sehn LH, Hertzberg M, Opat S. Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022; 6(2):533-543.","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"59757","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001; 79(4):373-374.","DOI":"10.4414\/fms.2001.04031"},{"key":"59758","doi-asserted-by":"crossref","unstructured":"Brice P, Bastion Y, Lepage E. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997; 15(3):1110-1117.","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"59759","doi-asserted-by":"crossref","unstructured":"Smith TJ, Bohlke K, Lyman GH. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(28):3199-3212.","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"59760","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"59761","doi-asserted-by":"crossref","unstructured":"Cheson BD, Chua N, Mayer J. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018; 36(22):2259-2266.","DOI":"10.1200\/JCO.2017.76.3656"},{"key":"59762","doi-asserted-by":"crossref","unstructured":"Leonard JP, Trneny M, Izutsu K. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019; 37(14):1188-1199.","DOI":"10.1200\/JCO.19.00010"},{"key":"59763","doi-asserted-by":"crossref","unstructured":"Tilly H, Morschhauser F, Bartlett NL. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019; 20(7):998-1010.","DOI":"10.1016\/S1470-2045(19)30091-9"},{"key":"59764","doi-asserted-by":"crossref","unstructured":"Hagemeister F, Manoukian G. Bendamustine in the treatment of non-Hodgkin\u2019s lymphomas. Onco Targets Ther. 2009; 2:269-279.","DOI":"10.2147\/OTT.S4873"},{"key":"59765","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"59766","doi-asserted-by":"crossref","unstructured":"Erblich T, Montoto S. Treating relapsed follicular lymphoma. Expert Rev Hematol. 2018; 11(5):403-410.","DOI":"10.1080\/17474086.2018.1453801"},{"key":"59767","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Schmitz S, Cogliatti S. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004; 103(12):4416-4423.","DOI":"10.1182\/blood-2003-10-3411"},{"key":"59768","unstructured":"Liewer S. Toxicity of bendamustine therapy. The Oncology Pharmacist. 2021."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283557\/76147","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283557\/76788","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11281\/76147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:57Z","timestamp":1794045897000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283557","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}